Medical oncologist Jedd Wolchok has received the 38th annual AACR Richard and Hinda Rosenthal Memorial Award for his work with melanoma immunotherapy by the American Association for Cancer Research. This prestigious award was presented to Dr. Wolchok at the AACR Annual Meeting 2014, held in San Diego April 5–9.
In addition, Dr. Wolchok has been appointed Chief of the Melanoma and Immunotherapeutics Service, Division of Solid Tumor Oncology in the Department of Medicine. This service was originally part of the Melanoma and Sarcoma Service, which split into two services earlier this year.
In this new role Dr. Wolchok will continue the on-going research efforts of the Memorial Sloan Kettering team, a world leader in melanoma management and the evaluation of new immunotherapeutics.
Dr. Wolchok is also the Associate Director of the Ludwig Center for Cancer Immunotherapy. He has been the lead investigator of pivotal clinical trials of new immunotherapy drugs ipilimumab and nivolumab. Amongst other goals, his research focuses ondeveloping improved ways to use the immune system to treat cancer, investigating pathways that regulate effective T-cell therapy, and conducting clinical trials to test potential new immune therapy based on laboratory research.